1. Home
  2. CNEY vs NVNO Comparison

CNEY vs NVNO Comparison

Compare CNEY & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

N/A

Current Price

$0.82

Market Cap

5.7M

Sector

Industrials

ML Signal

N/A

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

N/A

Current Price

$11.96

Market Cap

6.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNEY
NVNO
Founded
2009
1987
Country
China
United States
Employees
N/A
37
Industry
Major Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CNEY
NVNO
Price
$0.82
$11.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
136.1K
10.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.30
52 Week High
$3.25
$12.85

Technical Indicators

Market Signals
Indicator
CNEY
NVNO
Relative Strength Index (RSI) 38.56 63.94
Support Level $0.54 $0.49
Resistance Level $1.10 $12.64
Average True Range (ATR) 0.10 1.25
MACD -0.03 -0.08
Stochastic Oscillator 10.22 78.03

Price Performance

Historical Comparison
CNEY
NVNO

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: